| LAUSEKER, Michael, Katharina BACHL, Anna TURKINA, Edgar FABER, Witold PREJZNER, Ulla OLSSON-STROMBERG,, Michele BACCARANI, Elza LOMAIA, Daniela ŽÁČKOVÁ, Gert OSSENKOPPELE, Laimonas GRISKEVICIUS, Gabriele SCHUBERT-FRITSCHLE, Tomasz SACHA, Sonja HEIBL, Perttu KOSKENVESA, Andrija BOGDANOVIC, Richard E. CLARK, Joelle GUILHOT, Verena S. HOFFMANN, Joerg HASFORD, Andreas HOCHHAUS and Markus PFIRRMANN. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American Journal of Hematology. Hoboken: John Wiley & Sons, 2019, vol. 94, No 11, p. 1236-1243. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25628. |
Other formats:
BibTeX
LaTeX
RIS
@article{1605421,
author = {Lauseker, Michael and Bachl, Katharina and Turkina, Anna and Faber, Edgar and Prejzner, Witold and OlssonandStromberg,, Ulla and Baccarani, Michele and Lomaia, Elza and Žáčková, Daniela and Ossenkoppele, Gert and Griskevicius, Laimonas and SchubertandFritschle, Gabriele and Sacha, Tomasz and Heibl, Sonja and Koskenvesa, Perttu and Bogdanovic, Andrija and Clark, Richard E. and Guilhot, Joelle and Hoffmann, Verena S. and Hasford, Joerg and Hochhaus, Andreas and Pfirrmann, Markus},
article_location = {Hoboken},
article_number = {11},
doi = {http://dx.doi.org/10.1002/ajh.25628},
keywords = {WORLD-HEALTH-ORGANIZATION; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; 2904 CML PATIENTS; RANDOMIZED CML; SURVIVAL; MANAGEMENT; IMATINIB; ERA; RECOMMENDATIONS},
language = {eng},
issn = {0361-8609},
journal = {American Journal of Hematology},
title = {Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin},
url = {http://dx.doi.org/10.1002/ajh.25628},
volume = {94},
year = {2019}
}
TY - JOUR
ID - 1605421
AU - Lauseker, Michael - Bachl, Katharina - Turkina, Anna - Faber, Edgar - Prejzner, Witold - Olsson-Stromberg,, Ulla - Baccarani, Michele - Lomaia, Elza - Žáčková, Daniela - Ossenkoppele, Gert - Griskevicius, Laimonas - Schubert-Fritschle, Gabriele - Sacha, Tomasz - Heibl, Sonja - Koskenvesa, Perttu - Bogdanovic, Andrija - Clark, Richard E. - Guilhot, Joelle - Hoffmann, Verena S. - Hasford, Joerg - Hochhaus, Andreas - Pfirrmann, Markus
PY - 2019
TI - Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
JF - American Journal of Hematology
VL - 94
IS - 11
SP - 1236-1243
EP - 1236-1243
PB - John Wiley & Sons
SN - 03618609
KW - WORLD-HEALTH-ORGANIZATION
KW - CHRONIC MYELOGENOUS LEUKEMIA
KW - TYROSINE KINASE INHIBITORS
KW - 2904 CML PATIENTS
KW - RANDOMIZED CML
KW - SURVIVAL
KW - MANAGEMENT
KW - IMATINIB
KW - ERA
KW - RECOMMENDATIONS
UR - http://dx.doi.org/10.1002/ajh.25628
L2 - http://dx.doi.org/10.1002/ajh.25628
N2 - Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.
ER -
LAUSEKER, Michael, Katharina BACHL, Anna TURKINA, Edgar FABER, Witold PREJZNER, Ulla OLSSON-STROMBERG,, Michele BACCARANI, Elza LOMAIA, Daniela ŽÁČKOVÁ, Gert OSSENKOPPELE, Laimonas GRISKEVICIUS, Gabriele SCHUBERT-FRITSCHLE, Tomasz SACHA, Sonja HEIBL, Perttu KOSKENVESA, Andrija BOGDANOVIC, Richard E. CLARK, Joelle GUILHOT, Verena S. HOFFMANN, Joerg HASFORD, Andreas HOCHHAUS and Markus PFIRRMANN. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2019, vol.~94, No~11, p.~1236-1243. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25628.
|
